Preparation method and application of anti-photoaging composition for sensitive skin

Abstract

The invention relates to a preparation method and application of an anti-photoaging composition for sensitive skin, and belongs to the technical field of cosmetics, the anti-photoaging composition for sensitive skin comprises the following components: EGCG nanocrystal, hydrolyzed gardenia extract, nonapeptide-1 and aureobasidium pullulans polysaccharide, and the EGCG nanocrystal is prepared by a precipitation-high pressure homogenization method. The EGCG nanocrystal, the hydrolyzed gardenia extract, the nonapeptide-1 and the pullulan are compounded for use to jointly construct a four-dimensional synergistic protection system of resisting oxidation, promoting collagen generation, inhibiting melanin and reconstructing a barrier, so that an efficient, stable and low-irritation brand-new solution is provided for the field of light aging resistance; the clinical application value and the market prospect are obvious.

Description

Technical Field

[0001] This invention belongs to the field of cosmetic technology and relates to a method for preparing and applying an anti-photoaging composition for sensitive skin. Background Technology

[0002] With increasing environmental pollution and more frequent outdoor activities, photoaging of the skin has become one of the major challenges facing skin health management. Currently, mainstream anti-aging technologies primarily address UV-induced damage through single or limited pathways such as anti-oxidation, anti-inflammation, and collagen synthesis promotion. However, this approach suffers from three major drawbacks: First, single antioxidant / peptide / plant extract systems have limited target areas. Photoaging itself is a complex biological process involving multiple pathways such as oxidative stress, inflammatory responses, and DNA damage. Targeting only certain aspects of photoaging, such as oxidation and collagen degradation, cannot provide a comprehensive "protection-repair-reconstruction" protection chain. Second, some active ingredients, such as vitamin C, EGCG, and peptides, have large molecular weights and poor water solubility, resulting in transdermal efficiency generally below 10%. This means that most active ingredients cannot effectively reach their targets to exert physiological effects. Furthermore, EGCG and other active ingredients are easily oxidized and inactivated, requiring complex encapsulation techniques, which significantly increases the complexity of formulations, production costs, and the difficulty of process control. Third, some products, in pursuit of significant efficacy, often add high concentrations of active ingredients such as 5% vitamin C or EGCG. However, this often directly conflicts with skin tolerance, especially the suitability for sensitive skin, thus limiting their effective application in a wider range of people, particularly those with sensitive skin. Summary of the Invention

[0003] The purpose of this invention is to provide a method for preparing and applying an anti-photoaging composition for sensitive skin. This invention uses EGCG nanocrystals, hydrolyzed gardenia extract, nonapeptide-1, and budding short stem enzyme polysaccharide in combination to jointly construct a four-dimensional synergistic protection system of "antioxidant-promoting collagen production-inhibiting melanin-barrier reconstruction". This provides a new, efficient, stable, and low-irritation solution for the field of anti-photoaging, and has significant clinical application value and market prospects.

[0004] The objective of this invention can be achieved through the following technical solutions: In a first aspect, the present invention provides a sensitive skin anti-photoaging composition, the composition comprising the following components: EGCG nanocrystals, hydrolyzed gardenia extract, nonapeptide-1, and budding short stalk enzyme polysaccharide, wherein the weight ratio of EGCG nanocrystals, hydrolyzed gardenia extract, nonapeptide-1, and budding short stalk enzyme polysaccharide is (0.5-3):(0.005-0.03):(0.1-1):(0.1-0.5), and the EGCG nanocrystals are obtained by precipitation-high pressure homogenization of EGCG.

[0005] Preferably, the weight ratio of EGCG nanocrystals, hydrolyzed gardenia extract, nonapeptide-1, and budding short stem enzyme polysaccharide is (1-1.2):(0.01-0.02):(0.4-0.6):(0.2-0.3).

[0006] Specifically, the preparation method of the EGCG nanocrystals includes the following steps: S1. Add EGCG to anhydrous ethanol and stir at 25℃ and 200-400 r / min until completely dissolved to obtain an EGCG solution. S2. At 25℃ and 300-500r / min, EGCG solution and precipitant are added dropwise to distilled water for precipitation. After both EGCG solution and precipitant have been added, stir for 30-45min to obtain a mixture. S3. Centrifuge the mixture at 4℃ and 6000-10000r / min for 10-20min and discard the supernatant. Add 3-4 times the volume of distilled water to the centrifuge tube and gently stir with a glass rod to resuspend the precipitate. Centrifuge again under the same conditions for 10-20min and discard the supernatant. Repeat this washing operation twice to obtain the washed EGCG nanocrystal precipitate. S4. Add 3-4 times the volume of distilled water to the washed EGCG nanocrystal precipitate and stir at 200-400 r / min to obtain an EGCG nanocrystal suspension. S5. Transfer the EGCG nanocrystal suspension to a high-pressure homogenizer, homogenize at low pressure for 2-3 minutes, then homogenize at high pressure for 1-3 minutes, repeat 10 times to obtain EGCG nanocrystals.

[0007] Preferably, the concentration of the EGCG solution in step S1 is 0.01-0.03 g / mL.

[0008] Preferably, the precipitant in step S2 is a 0.05-0.15 mol / L acetic acid solution, the volume ratio of the EGCG solution, precipitant and distilled water is 1:(1-3):(20-50), the dropping rate of the EGCG solution and the precipitant is 1-2 drops / s, the dropping time is 30-90 min, and the pH value of the system is stably controlled at 6 by adding 0.1 mol / L sodium hydroxide solution or 0.1 mol / L acetic acid solution.

[0009] Preferably, the pressure of the low-pressure homogenization in step S5 is 40-60 bar, the pressure of the high-pressure homogenization is 280-320 bar, the average particle size of the EGCG nanocrystals is 150-200 nm, and the absolute value of the ZETA potential is greater than 30 mV.

[0010] Secondly, the present invention provides a method for preparing an anti-photoaging composition for sensitive skin, comprising the following steps: EGCG nanocrystals, hydrolyzed gardenia extract, nonapeptide-1, and budding short stem enzyme polysaccharide were mixed evenly in a certain weight ratio to obtain a sensitive skin anti-photoaging composition.

[0011] Thirdly, the present invention provides the application of the sensitive skin anti-photoaging composition of the second aspect in the preparation of skin care products, the skin care products including toners, lotions, creams, masks, serums, and sprays.

[0012] Fourthly, the present invention provides an emulsion comprising the following ingredients by weight percentage: 5%-20% of the sensitive skin anti-photoaging composition of the second aspect, 0.05%-0.5% thickener, 1%-10% moisturizer, 0.01%-0.3% pH adjuster, 1%-6% emulsifier, 5%-15% oil, 0.5%-3% preservative, and the balance being deionized water.

[0013] Preferably, the thickener comprises at least one of xanthan gum, carbomer, hydroxyethyl acrylate / sodium acryloyl dimethyl taurate copolymer, ammonium acryloyl dimethyl taurate / VP copolymer, and hydroxyethyl cellulose; Preferably, the moisturizer includes at least one of allantoin, sodium polyacrylate, panthenol, β-glucan, trehalose, caprylyl glycol, dipropylene glycol, sodium hyaluronate, 1,2-butanediol, glycerin, and tremella polysaccharide.

[0014] Preferably, the pH adjuster includes at least one of arginine, citric acid, and NaOH.

[0015] Preferably, the emulsifier comprises at least one of PEG-100 glyceryl stearate, glyceryl stearate citrate, cetearyl glucoside, cetyl alcohol, stearyl alcohol, cetearyl alcohol, PEG-20 methyl glucose sesquistearate, methyl glucose sesquistearate, cetyl phosphate potassium, and sodium stearoyl glutamate.

[0016] Preferably, the oil comprises at least one of caprylic / capric triglyceride, polydimethylsiloxane, jojoba oil, grape seed oil, meadowfoam seed oil, squalane, macadamia nut oil, and camellia oil.

[0017] Preferably, the preservative includes at least one selected from 1,2-hexanediol, 1,2-pentanediol, ethylhexylglycerin, p-hydroxyacetophenone, phenoxyethanol, octanoyl hydroxamic acid, and sodium benzoate.

[0018] The beneficial effects of this invention are: The sensitive skin anti-photoaging composition provided by this invention includes EGCG nanocrystals, hydrolyzed gardenia extract, nonapeptide-1, and budding short-stalk enzyme polysaccharide. The EGCG nanocrystals are prepared using a precipitation-high-pressure homogenization method, which significantly improves the solubility and transdermal absorption rate of EGCG. The hydrolyzed gardenia extract inhibits UVA-induced MMP-1 expression. Nonapeptide-1 competitively inhibits the binding of α-MSH to MC1R receptors, blocking the signaling pathway of melanin synthesis, thereby reducing melanin production at its source and achieving whitening, spot-fading, and skin-evening effects. Budding short-stalk enzyme polysaccharide promotes keratinocyte migration and skin barrier repair. The combined use of EGCG nanocrystals, hydrolyzed gardenia extract, nonapeptide-1, and budding short-stalk enzyme polysaccharide constructs a four-dimensional synergistic protection system of "antioxidant-promoting collagen production-inhibiting melanin-barrier reconstruction."

[0019] This invention overcomes the bottleneck of transdermal absorption of active ingredients through nanocrystal technology and combines a multi-target synergistic mechanism to provide a novel, efficient, stable, and low-irritation solution for the field of anti-photoaging, with significant clinical application value and market prospects. Detailed Implementation

[0020] To further illustrate the technical means and effects of the present invention in achieving its intended purpose, the following detailed description of the specific implementation methods, structures, features, and effects of the present invention, in conjunction with embodiments, is provided below.

[0021] All EGCG used in the embodiments and comparative examples of this invention was purchased from Shanghai Yuanye Biotechnology Co., Ltd. (purity: HPLC ≥ 98%, catalog number: B20106); hydrolyzed gardenia extract was purchased from Shaanxi Yiruinong Biotechnology Co., Ltd., trade name: Gardenia Extract; nonapeptide-1 was purchased from Shanghai Yuanye Biotechnology Co., Ltd. (purity: 97%, catalog number: S94554-100mg); and budding short stalk enzyme polysaccharide was purchased from Nanjing Dulai Biotechnology Co., Ltd. (catalog number: C0200). Unless otherwise specified, all other materials, reagents, etc. used in all embodiments and comparative examples of this invention are commercially available.

[0022] The components and their weight ratios of the sensitive skin anti-photoaging compositions in Examples 1-5 and Comparative Examples 1-8 are shown in Table 1. The total weight of the compositions in each example and comparative example is equal. The preparation method of each composition is as follows: the components are mixed according to the formula amount to obtain the sensitive skin anti-photoaging compositions.

[0023] Table 1. Components and weight ratios of the composition

[0024] The preparation methods of EGCG nanocrystals in Examples 1-5 and Comparative Examples 2-6 include the following steps: S1. Add EGCG to anhydrous ethanol and stir at 25℃ and 300r / min until completely dissolved to obtain an EGCG solution with a concentration of 0.02g / mL. S2. At 25℃ and 400r / min, a 0.02g / mL EGCG solution and a 0.1mol / L acetic acid solution were added dropwise to distilled water for precipitation. The volume ratio of the EGCG solution, acetic acid solution, and distilled water was 1:2:35. The dropping rate of the EGCG solution and the precipitant was 1.5 drops / s, and the dropping time was 60min. The pH value of the system was stabilized at 6 by adding 0.1mol / L sodium hydroxide solution or 0.1mol / L acetic acid solution. After the EGCG solution and acetic acid solution were added, the mixture was stirred for another 40min to obtain a mixed solution. S3. Centrifuge the mixture at 4℃ and 8000r / min for 15min and discard the supernatant. Add 3.5 times the volume of distilled water to the centrifuge tube and gently stir with a glass rod to resuspend the precipitate. Centrifuge again under the same conditions for 15min and discard the supernatant. Repeat this washing operation twice to obtain the washed EGCG nanocrystal precipitate. S4. Add 3.5 times the volume of distilled water to the washed EGCG nanocrystal precipitate and stir at 300 r / min to obtain an EGCG nanocrystal suspension. S5. Transfer the EGCG nanocrystal suspension to a high-pressure homogenizer, homogenize at 50 bar for 2.5 min, then homogenize at 300 bar for 2 min, repeat 10 times to obtain EGCG nanocrystals with an average particle size of 175 nm and an absolute value of ZETA potential greater than 30 mV.

[0025] Comparative Example 7 Compared with Example 1, the difference is that Comparative Example 7 uses EGCG instead of EGCG nanocrystals in Example 1, while other conditions remain the same as in Example 1.

[0026] Comparative Example 8 Compared with Example 1, the difference is that Comparative Example 8 uses the washed EGCG nanocrystal precipitate obtained in step S3 to replace the EGCG nanocrystals in Example 1, while other conditions remain the same as in Example 1.

[0027] Test Example 1: In vitro DPPH free radical scavenging test a. Experimental steps DPPH solution preparation: Weigh 4 mg of DPPH powder, dissolve it in 60% v / v ethanol aqueous solution, and make up to 100 mL. Final concentration: approximately 40 mg / L. Sonicate for 5 min to aid dissolution and store in the dark. Sample solution preparation: Using the compositions of Examples 1-5 and Comparative Examples 1-8 as samples, weigh the corresponding samples, dissolve and dilute them with 60% v / v ethanol aqueous solution to prepare a sample solution with a concentration of 5 mg / mL.

[0028] b. Experimental Groups: Blank control group (A0): 2 mL sample solution + 2 mL 60% v / v ethanol aqueous solution; Sample group (A1): 2 mL sample solution + 2 mL DPPH solution; Sample matrix group (A2): 2 mL DPPH solution + 2 mL 60% v / v ethanol aqueous solution; Reaction: After mixing each group evenly, let it stand in the dark for 30 minutes, centrifuge at 5000 r / min for 10 minutes, take the supernatant, and measure the absorbance at a wavelength of 517 nm.

[0029] c. Parallel experiments and replication Three parallel tubes were set up for each sample, and the average value of the results was taken.

[0030] d. Data calculation and result analysis The formula for DPPH free radical scavenging rate is: Scavenging rate (%) = [1−(A1−A0) / A2]×100%; the results are shown in Table 2.

[0031] Test Example 2: Tyrosinase Activity Inhibition Test According to the "T / SHRH 015-2018 Cosmetics - Test Method for Tyrosinase Activity Inhibition", the positive control group was kojic acid at a concentration of 0.05 mg / mL (diluted with disodium hydrogen phosphate-citric acid buffer at pH 6.8), and the test substances were the compositions of Examples 1-5 and Comparative Examples 1-8 at a concentration of 0.5 mg / mL (diluted with disodium hydrogen phosphate-citric acid buffer at pH 6.8). Three parallel tests were set up for each test substance group, and the average value was taken. The raw material with tyrosinase activity inhibitory effect can reduce the conversion of dopa to dopaquinone, thereby reducing the absorbance. The inhibitory effect of the raw material on tyrosinase activity was evaluated based on the change in absorbance, and the results are shown in Table 2.

[0032] Test Example 3: Anti-photoaging effect test a. Sample solution preparation The compositions of Examples 1-5 and Comparative Examples 1-8 were used as samples and diluted with PBS solution to a concentration of 100 μg / mL.

[0033] b. Cell Culture and Inoculation Human fibroblasts were seeded in T75 culture flasks and cultured in DMEM medium containing 10% v / v FBS at 37°C and 5% CO2. When the cells reached the logarithmic growth phase, they were digested with 0.25% trypsin-EDTA to adjust the cell density to an appropriate level (e.g., 2 × 10⁶ cells / year). 5 (cells / mL) were seeded into 96-well plates and incubated in a CO2 incubator for 24 h. The complete culture medium in the wells was then aspirated, and each group was washed repeatedly with an appropriate amount of PBS until colorless.

[0034] c. Experimental Grouping The UVA group and the experimental group were each added to 200 μL of PBS solution and irradiated for 60 s under UVA conditions with an irradiation dose of 30 mJ / cm² and a light source intensity of 0.5 mW / cm². The PBS was then discarded. The UVA group was added to 100 μL of PBS solution and 100 μL of culture medium, while the experimental group was added to 100 μL of sample solution and 100 μL of culture medium.

[0035] The UVA group and the experimental group were incubated at 37℃ and 5% CO2 for 48 hours; three parallel experiments were set up for each group.

[0036] d. Sample collection and collagen detection Cell lysis: After irradiation, discard the culture medium, gently wash the cells twice with PBS, add 50 μL of RIPA cell lysis buffer containing protease inhibitors to each well, and lyse the cells on ice for 30 min, gently shaking occasionally to ensure complete lysis. After lysis, transfer the lysis buffer to centrifuge tubes, centrifuge at 12000 rpm for 10 min at 4°C, and collect the supernatant. Type I collagen detection: Follow the instructions of the Human Type I Collagen (Col I) ELISA Kit (Shanghai Enzyme-Link Biotechnology Co., Ltd.) to mix the supernatant with the reagents in the kit and react. Then, use an ELISA reader to detect the absorbance of the reaction product and calculate the type I collagen content based on the standard curve. The rate of change in collagen in each embodiment and comparative example was calculated using the following formula: The increase rate of type I collagen (%) = (type I collagen content in the sample group - type I collagen content in the UVA group) / type I collagen content in the UVA group × 100%, and the results are shown in Table 2.

[0037] Table 2 Results of Test Examples 1-3 Group DPPH removal rate / % Tyrosinase inhibition rate / % Collagen increase rate / % Positive control group \ 85.0 \ Example 1 98.1 83.3 295.8 Example 2 96.9 82.1 281.6 Example 3 96.2 80.9 264.9 Example 4 93.4 75.5 203.7 Example 5 94.7 78.6 235.1 Comparative Example 1 65.5 48.3 63.9 Comparative Example 2 68.8 54.7 75.4 Comparative Example 3 72.6 51.8 50.8 Comparative Example 4 75.0 62.5 81.6 Comparative Example 5 78.3 64.4 96.3 Comparative Example 6 85.5 66.1 110.7 Comparative Example 7 88.4 71.3 139.4 Comparative Example 8 90.1 73.8 162.5 As shown in Table 2, the present invention utilizes EGCG nanocrystals, hydrolyzed gardenia extract, nonapeptide-1, and budding short stem enzyme polysaccharide to jointly construct a four-dimensional synergistic protection system of "antioxidant-promoting collagen production-inhibiting melanin-barrier reconstruction".

[0038] As shown in Example 1 and Comparative Examples 1-8, the proportions of EGCG nanocrystals, hydrolyzed gardenia extract, nonapeptide-1, and budding short stem enzyme polysaccharide, as well as the selection of raw materials, affect the composition's DPPH scavenging effect, tyrosinase inhibition effect, and collagen production promotion effect. When the weight ratio of EGCG nanocrystals, hydrolyzed gardenia extract, nonapeptide-1, and budding short stem enzyme polysaccharide is (1-1.2):(0.01-0.02):(0.4-0.6):(0.2-0.3), the composition exhibits significantly better DPPH scavenging, tyrosinase inhibition, and collagen production promotion effects.

[0039] Application Example 1-5 and Comparative Application Example 1-8 The compositions of Examples 1-5 and Comparative Examples 1-8 were added to the emulsion at a concentration of 5 wt% to obtain the emulsions of Application Examples 1-5 and Comparative Application Examples 1-8, respectively. In addition, an emulsion without the addition of the composition was prepared as a blank application example. The formulation of the emulsions is shown in Table 3.

[0040] Table 3 Emulsion components and dosage

[0041] The emulsion is prepared by: (1) After mixing the thickener, humectant and deionized water evenly, heat it in a water bath at 75°C for 10 min, homogenize it in a homogenizer at 4000 rpm for 5 min, and keep it at 75°C for later use to obtain the pre-prepared component A. (2) After mixing the oil and emulsifier, heat to 75°C, stir evenly, and keep warm at 75°C for later use to obtain pre-prepared component B; (3) Mix pre-prepared component A with pre-prepared component B and homogenize in a homogenizer at 4000 rpm for 5 min to obtain emulsified base material; (4) Stir the emulsion base material and cool it down to 50°C. Add the sensitive skin anti-photoaging composition and continue stirring until the material is uniform. Then add the preservative and pH adjuster to adjust the pH. After stirring evenly, stop stirring and discharge the material to obtain the emulsion.

[0042] Effect test: 1. Human skin patch test Forty-five participants were selected for testing according to the inclusion criteria, and the sample size was no more than 50 mm². 2A qualified spot test apparatus with a depth of approximately 1 mm was used. The sample was placed in the small chamber of the spot test apparatus. The spot test apparatus containing an equal volume (0.020 mL-0.025 mL) of the test sample (the emulsion prepared in Application Examples 1-5, Control Application Examples 1-8, and the blank application example, and distilled water) was applied to the flexor side of the subject's forearm with hypoallergenic adhesive tape. The palm was used to gently press the sample to ensure even application to the skin, and the application was maintained for 24 hours. Skin reactions were observed according to the standards in Table 4 at 30 min (after the indentation disappeared), 24 h, and 48 h after the spot test apparatus was removed, and the observation results were recorded.

[0043] Result determination: If more than 5 out of 45 subjects showed a suspected Grade 1 skin reaction, or more than 2 subjects showed a weakly positive Grade 2 skin reaction, or if any one subject showed a Grade 3 or higher adverse skin reaction, the test substance was determined to have an adverse skin reaction on the human body.

[0044] Table 4 Skin Reaction Grading Standards Rating levels Skin reaction 0 negative reaction 1 Suspicious reaction, only slight erythema 2 Weak positive reaction (erythema reaction): erythema, infiltration, edema, and papules may be present. 3 Strong positive reaction (herpes reaction): erythema, infiltration, edema, papules; the reaction may extend beyond the test area. 4 Extremely strong positive reaction (confluent herpes simplex reaction): obvious erythema, severe infiltration, edema, confluent herpes simplex; reaction extends beyond the test area. After testing, the anti-photoaging emulsions provided in Application Examples 1-5 and Comparative Application Examples 1-8 of the present invention showed negative reactions after human patch testing, indicating that they are safe and non-irritating to human skin.

[0045] 2. Human body anti-wrinkle, soothing and repair efficacy test Forty-two participants (healthy men or women aged 30-60) were selected according to the inclusion criteria to participate in the test. They used sample groups of the test product (lotions prepared as application examples 1-5, control examples 1-8, and a blank application example), with three participants in each group. The PRIMOS-CR skin test probe and the Tewameter®™ Hex transepidermal water loss probe were used to detect facial wrinkles and TEWL values ​​before product use (day 0), and on days 14, 28, and 56 after product use. This allowed for a comprehensive evaluation of the anti-wrinkle efficacy and soothing repair effect of the test product. Specific experimental parameters and equipment are shown in Table 5, and evaluation parameters are shown in Table 6.

[0046] Result determination: If the Wrinkle Area value of the test area decreases significantly after product use, it indicates that the test sample has an anti-wrinkle effect; conversely, if all parameters increase without significant difference, it indicates that the test product does not have an anti-wrinkle effect.

[0047] Table 5 Test Parameters and Equipment Rating levels Test time Test time point instrument Test metrics Number of people collected anti-wrinkle 56 days 0 / 14 / 28 / 56 days PRIMOS-CR Wrinkle Area value (crow's feet, under-eye wrinkles, nasolabial folds) / Wrinkle Length value (crow's feet, under-eye wrinkles, nasolabial folds) 42 Repair 56 days 0 / 14 / 28 / 56 days Tewameter®™ Hex TEWL value 42 Table 6 Evaluation Parameters Scoring parameters Parameter meaning Wrinkle Area Value The Wrinkle Area value represents the area of ​​wrinkles. The lower the Wrinkle Area value, the smaller the area of ​​crow's feet, under-eye wrinkles, and nasolabial folds. Wrinkle Length value The Wrinkle Length value represents the length of wrinkles. The lower the Wrinkle Length, the shorter the length of crow's feet, under-eye wrinkles, and nasolabial folds. TEWL value TEWL refers to the amount of water that evaporates from the skin surface into the environment per unit time (usually expressed in g / (m²·h)), reflecting the skin's stratum corneum's ability to retain moisture. Damage to the stratum corneum barrier (such as dryness, inflammation, over-cleansing, or UV damage) accelerates moisture loss, resulting in a higher TEWL value; conversely, an intact stratum corneum structure (such as tightly packed keratinocytes and an intact lipid layer) effectively prevents moisture loss, leading to a lower TEWL value. The formulas for calculating the improvement rate of each skin parameter before and after use are as follows: Improvement rate = [(T0 sample group - T14, 28, 56 sample groups) / T0 sample group × 100%].

[0048] The experimental results are averaged, as shown in Table 7 below: Table 7. Test Results of Anti-wrinkle, Soothing and Repairing Efficacy in Human Body

[0049] As shown in Table 7, the emulsion prepared using the composition of this invention has good anti-wrinkle and soothing repair effects. Specifically, when the weight ratio of EGCG nanocrystals, hydrolyzed gardenia extract, nonapeptide-1, and budding short-stem enzyme polysaccharide in the composition is (1-1.2):(0.01-0.02):(0.4-0.6):(0.2-0.3), the emulsion exhibits better anti-wrinkle and soothing repair effects. Furthermore, the EGCG nanocrystals obtained through the precipitation-high-pressure homogenization method of this invention, when combined with hydrolyzed gardenia extract, nonapeptide-1, and budding short-stem enzyme polysaccharide, are more easily absorbed through the skin compared to EGCG and unhomogenized EGCG nanocrystal precipitates, thus maximizing the anti-wrinkle and soothing repair effects.

[0050] The above description is merely a preferred embodiment of the present invention and is not intended to limit the present invention in any way. Although the present invention has been disclosed above with reference to preferred embodiments, it is not intended to limit the present invention. Any person skilled in the art can make some modifications or alterations to the above-disclosed technical content to create equivalent embodiments without departing from the scope of the present invention. Any indirect modifications, equivalent changes, and alterations made to the above embodiments based on the technical essence of the present invention without departing from the scope of the present invention shall still fall within the scope of the present invention.

Claims

1. A sensitive skin anti-photoaging composition characterized in that, The composition comprises the following components: EGCG nanocrystals, hydrolyzed gardenia extract, nonapeptide-1, and sphaeropsis balustinus polysaccharide, and the weight ratio of the EGCG nanocrystals, the hydrolyzed gardenia extract, the nonapeptide-1, and the sphaeropsis balustinus polysaccharide is (0.5-3):(0.005-0.03):(0.1-1):(0.1-0.5), and the EGCG nanocrystals are prepared by a precipitation-high-pressure homogenization method.

2. The sensitive skin anti-photoaging composition according to claim 1, characterized in that, The weight ratio of the EGCG nanocrystals, the hydrolyzed gardenia extract, the nonapeptide-1, and the sphaeropsis balustinus polysaccharide is (1-1.2):(0.01-0.02):(0.4-0.6):(0.2-0.3).

3. The sensitive skin anti-photoaging composition according to claim 1, characterized in that, The preparation method of the EGCG nanocrystals comprises the following steps: S1, EGCG is added to anhydrous ethanol, and stirred at 25 DEG C and 200-400 r / min until completely dissolved to obtain an EGCG solution; S2, the EGCG solution and a precipitant are simultaneously added dropwise into distilled water at 25 DEG C and 300-500 r / min for precipitation, and after the EGCG solution and the precipitant are both added dropwise, stirring is continued for 30-45 min to obtain a mixed solution; S3, the mixed solution is centrifuged at 4 DEG C and 6000-10000 r / min for 10-20 min, and the supernatant is discarded; 3-4 times the volume of distilled water is added into the centrifuge tube, and the precipitate is resuspended by gently stirring with a glass rod; the centrifuge tube is centrifuged again under the same conditions for 10-20 min, and the supernatant is discarded; the washing operation is repeated twice to obtain a washed EGCG nanocrystal precipitate; S4, 3-4 times the volume of distilled water is added into the washed EGCG nanocrystal precipitate, and stirred uniformly at 200-400 r / min to obtain an EGCG nanocrystal suspension; S5, the EGCG nanocrystal suspension is transferred into a high-pressure homogenizer, and subjected to low-pressure homogenization for 2-3 min, and then high-pressure homogenization for 1-3 min, and the cycle is repeated for 10 times to obtain EGCG nanocrystals.

4. The sensitive skin anti-photoaging composition according to claim 3, characterized in that, The concentration of the EGCG solution in step S1 is 0.01-0.03 g / mL.

5. The sensitive skin anti-photoaging composition according to claim 3, characterized in that, In step S2, the precipitant is 0.05-0.15 mol / L acetic acid solution, and the volume ratio of the EGCG solution, the precipitant, and distilled water is 1:(1-3):(20-50), the dropping speed of the EGCG solution and the precipitant is 1-2 drops / s, the dropping time is 30-90 min, and the pH value of the system is controlled at 6 by adding 0.1 mol / L sodium hydroxide solution or 0.1 mol / L acetic acid solution.

6. The sensitive skin anti-photoaging composition according to claim 3, characterized in that, In step S5, the pressure of the low-pressure homogenization is 40-60 bar, the pressure of the high-pressure homogenization is 280-320 bar, the average particle size of the EGCG nanocrystals is 150-200 nm, and the absolute value of the ZETA potential is greater than 30 mV.

7. A process for the preparation of a sensitive skin anti-photoaging composition according to any one of claims 1 to 6, characterized in that, The method comprises the following steps: The EGCG nanocrystals, the hydrolyzed gardenia extract, the nonapeptide-1, and the sphaeropsis balustinus polysaccharide are mixed uniformly according to the weight ratio to obtain a sensitive skin anti-photoaging composition.

8. Use of a sensitive skin anti-photoaging composition prepared according to the process of claim 7, characterized in that, The skin care product includes cosmetic water, emulsion, cream, mask, essence, and spray.

9. An emulsion characterized in that, The emulsion comprises the following raw materials by weight percentage: 5-20% of the sensitive skin anti-photoaging composition of claim 8, 0.05-0.5% of a thickening agent, 1-10% of a humectant, 0.01-0.3% of a pH regulator, 1-6% of an emulsifier, 5-15% of an oil, 0.5-3% of a preservative, and the balance is deionized water.

Images